Skip to main content
Premium Trial:

Request an Annual Quote

DNA Electronics Licenses IP to Ion Torrent

This article has been corrected to note that the agreement is non-exclusive.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – London-based DNA Electronics today announced a non-exclusive worldwide licensing agreement to provide sequencing technology firm Ion Torrent Systems access to its intellectual property.

No details of the agreement were disclosed.

DNA Electronics develops scalable semiconductor technology for real-time nucleic acid detection, "which enables faster, simpler, and more cost-effective DNA analysis platforms," it said in a statement. Its Genalysis platform delivers real-time, disposable, "accurate on-the-spot tests," according to the company's website.

Its IP portfolio includes label-free pH-mediated detection of DNA and RNA using semiconductor chips; DNA sequencing with chip-based detection of hydrogen ions that are released from nucleotide incorporation, novel power electronic interfacing methods; on-chip nucleic acid amplification methods; and on-chip SNP detection methods.

In March, Ion Torrent launched its electronic sequencer that reads DNA on a semiconductor chip by measuring the release of protons as nucleotides get incorporated by DNA polymerase.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.